Compass Therapeutics Shares Plunge After Mixed COMPANION-002 Results
Compass Therapeutics stock dropped 80% after the company released data from its COMPANION-002 Phase 2/3 trial of tovecimig in biliary tract cancer. The combination of tovecimig and paclitaxel improved progression-free survival and response rate but did not achieve statistical significance for overall survival, with the analysis confounded by substa…